Brief: Cyteir Therapeutics Says CYT-0851 Phase 1 Results Show Well Tolerated Safety Profile In Advanced Solid Tumors
05/06/2022 13:34
June 5 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYT-0851 PHASE 1 DOSE ESCALATION RESULTS SHOW EARLY
CLINICAL
ACTIVITY AND GENERALLY WELL TOLERATED SAFETY PROFILE IN ADVANCED
SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES
* CYTEIR THERAPEUTICS- CYT-0851 SHOWS BROAD CLINICAL
ACTIVITY AND
GENERALLY WELL TOLERATED SAFETY PROFILE IN A HEAVILY PRETREATED
POPULATION OF PATIENTS
* CYTEIR THERAPEUTICS- DURABLE RESPONSES SEEN IN BOTH SOLID
TUMORS, HEMATOLOGIC MALIGNANCIES IN DOSE ESCALATION WITH 44%
DISEASE CONTROL RATE
* CYTEIR THERAPEUTICS- CLINICAL ACTIVITY FROM PHASE 1 STUDY
SUPPORT CLINICAL DEVELOPMENT OF CYT-0851; DATA FROM STUDIES
EXPECTED IN SECOND HALF OF 2022
* CYTEIR THERAPEUTICS- CYT-0851 EXHIBITED GENERALLY WELL
TOLERATED
SAFETY PROFILE WITH 42% OF PATIENTS REPORTING NO TREATMENT
RELATED ADVERSE EVENTS
Source text for Eikon: ID:nBw9K2JdFa
Further company coverage: CYT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile